Production (Stage)
Hoth Therapeutics, Inc.
HOTH
$1.19
-$0.11-8.46%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.46% | 35.83% | 10.38% | 2.19% | 26.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.93% | 21.68% | 1.88% | -3.68% | -1.50% |
| Operating Income | -60.93% | -21.68% | -1.88% | 3.68% | 1.50% |
| Income Before Tax | -61.93% | -21.40% | -2.18% | 12.84% | 1.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -61.93% | -21.40% | -2.18% | 12.84% | 1.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -61.93% | -21.40% | -2.18% | 12.84% | 1.69% |
| EBIT | -60.93% | -21.68% | -1.88% | 3.68% | 1.50% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 44.04% | 27.66% | 48.44% | 58.15% | 44.51% |
| Normalized Basic EPS | 44.01% | 26.91% | 48.44% | 54.07% | 44.04% |
| EPS Diluted | 44.27% | 27.66% | 48.44% | 58.15% | 44.51% |
| Normalized Diluted EPS | 44.01% | 26.91% | 48.44% | 54.07% | 44.04% |
| Average Basic Shares Outstanding | 189.34% | 67.83% | 98.17% | 108.24% | 77.17% |
| Average Diluted Shares Outstanding | 189.34% | 67.83% | 98.17% | 108.24% | 77.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |